This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Regeneron has announced that the European Commission (EC) has approved Libtayo (cemiplimab) as a monotherapy for the treatment of adult patients with second-line recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy. The results were published in the New England Journal of Medicine.
The narrower label for Zejula (niraparib) means it can only be used as second-line maintenance therapy after platinum-based chemotherapy in patients with these cancers whose tumours carry a germline BRCA mutation – around 15% of the population. That was due last Friday, but cancelled when GSK opted to withdraw the approval.
New responsibilities, new arenas The potential for in-hospital manufacturing is further developing due to the new responsibilities assigned to hospital pharmacy staff, such as centralised preparation of chemotherapies and drugs for clinical trials, extemporaneous production of radiopharmaceuticals and cellular therapies, to name but a few.
People taking Enbrel can usually get vaccinations, but they should avoid live vaccines. Some studies suggest that Enbrel might slightly lower the body’s response to certain vaccines, like the pneumococcal vaccine. Similarly, live vaccines should also be avoided with Cosentyx due to similar safety concerns.
In cats, prednisolone is used as an add-on treatment to chemotherapy drugs or as a palliative treatment for advanced cancers. Live vaccines should be avoided because prednisone and prednisolone weaken the immune system. Store any compounded version of this medicine following the directions on the label.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content